⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of KingMylab and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
KingMylab
↗Guangzhou, China
KingMylab is a leading clinical research organization (CRO) in China, specializing in central laboratory and data services for clinical trials. Originally established in 2008 as the Clinical Trial Department of Guangzhou KingMed Diagnostics, it became an independent entity in 2020. The company provides one-stop, scientific, and compliant laboratory solutions, including bioanalysis, biomarker discovery, and clinical trial management, supporting pharmaceutical and biotech partners globally.
With state-of-the-art laboratories in Guangzhou, Shanghai, and Hong Kong, KingMylab covers the entire drug development lifecycle from preclinical discovery to Phase IV clinical trials. The company has supported over 800 clients and participated in nearly 4,500 clinical trials, contributing to the approval of more than 90 new drugs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2020
Ownership:private
Status:operating
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Small molecule, Antibodies (mAb/bispecific), Cell therapy, Gene therapy, Vaccines
Active Trials:4500
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:KingMylab Pharmaceutical Research (HK) Limited
Key Partnerships:VisMederi (Strategic collaboration for vaccine and biologics testing)
COMPETITION
Position:Leader
Competitors:Boji Pharmaceutical, Other major Chinese and global central labs
LEADERSHIP
Key Executives:
Jiangtao Xie - CEO
Shihui Yu - Chief Scientific Advisor
LINKS
Website:kingmylab.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with KingMylab. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.